Literature DB >> 21901538

Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo.

Chunmei Wang1, Guangyao Sheng, Jie Lu, Lei Xie, Songting Bai, Yingchao Wang, Yufeng Liu.   

Abstract

NF-κB p65 is found constitutively active in acute monocytic leukemia, and has been considered an important factor for poor prognosis. Therefore, develop specifically target p65 inhibitors will be substantial interest. Until now, although several p65 inhibitors are currently in preclinical and clinical development, none of them are targeting. In this study, siRNA targeting p65 was introduced into the acute monocytic leukemia cell line THP-1 and THP-1 xenograft tumors in nude mice, and then, we measured p65 mRNA and protein levels by real-time RT-PCR and Western blotting, and levels of related protein cyclin D1, Bc1-2, and SMRT by Western blotting. We also investigated the cell cycle and apoptosis via FCM, and cell proliferation by Cell Counting Kit-8 assay. We found that p65 siRNA could effectively reduce the p65 mRNA and protein expression, arrest cells in G0/G1 phase, inhibit the proliferation and increase the apoptosis of THP-1 cells, and intratumoral injection of p65 siRNA could suppress tumor growth in nude mice. We also found that when down regulation of p65, the expression of cyclin D1 and Bc1-2 decreased, and the expression of SMRT increased in vitro and vivo. All these findings suggest that NF-κB p65 maybe an attractive candidate for the therapeutic targeting of acute monocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901538     DOI: 10.1007/s11010-011-1006-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  36 in total

Review 1.  Transcriptional regulation via the NF-kappaB signaling module.

Authors:  A Hoffmann; G Natoli; G Ghosh
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

2.  Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.

Authors:  B E S Gibson; K Wheatley; I M Hann; R F Stevens; D Webb; R K Hills; S S N De Graaf; C J Harrison
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

3.  Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.

Authors:  Y Ravindranath; M Chang; C P Steuber; D Becton; G Dahl; C Civin; B Camitta; A Carroll; S C Raimondi; H J Weinstein
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

4.  Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000.

Authors:  R C Ribeiro; B I Razzouk; S Pounds; N Hijiya; C-H Pui; J E Rubnitz
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

5.  Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.

Authors:  Sabrina Höbel; Ivette Koburger; Matthias John; Frank Czubayko; Philipp Hadwiger; Hans-Peter Vornlocher; Achim Aigner
Journal:  J Gene Med       Date:  2010-03       Impact factor: 4.565

6.  An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Authors:  Monica L Guzman; Randall M Rossi; Sundar Neelakantan; Xiaojie Li; Cheryl A Corbett; Duane C Hassane; Michael W Becker; John M Bennett; Edmund Sullivan; Joshua L Lachowicz; Andrew Vaughan; Christopher J Sweeney; William Matthews; Martin Carroll; Jane L Liesveld; Peter A Crooks; Craig T Jordan
Journal:  Blood       Date:  2007-09-05       Impact factor: 22.113

7.  Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.

Authors:  Tomohiro Kitamura; Masaki Itoh; Tetsuo Noda; Mamoru Matsuura; Keiji Wakabayashi
Journal:  Int J Cancer       Date:  2004-04-20       Impact factor: 7.396

8.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

9.  NF-kappa B genes have a major role in inflammatory breast cancer.

Authors:  Florence Lerebours; Sophie Vacher; Catherine Andrieu; Marc Espie; Michel Marty; Rosette Lidereau; Ivan Bieche
Journal:  BMC Cancer       Date:  2008-02-04       Impact factor: 4.430

10.  The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome.

Authors:  Andrew R Green; Claire Burney; Christopher J Granger; E Claire Paish; Somaia El-Sheikh; Emad A Rakha; Desmond G Powe; R Douglas Macmillan; Ian O Ellis; Eleni Stylianou
Journal:  Breast Cancer Res Treat       Date:  2007-09-28       Impact factor: 4.872

View more
  4 in total

1.  Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells.

Authors:  D Yang; L Li; H Liu; L Wu; Z Luo; H Li; S Zheng; H Gao; Y Chu; Y Sun; J Liu; L Jia
Journal:  Cell Death Differ       Date:  2012-08-31       Impact factor: 15.828

2.  Nuclear factor-kappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by 131I.

Authors:  Zhaowei Meng; Shanshan Lou; Jian Tan; Ke Xu; Qiang Jia; Wei Zheng
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

3.  Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells.

Authors:  Yingchao Wang; Lina Ma; Chunmei Wang; Guangyao Sheng; Lei Feng; Chuyun Yin
Journal:  Int J Mol Med       Date:  2015-06-30       Impact factor: 4.101

4.  Efficient Treatment of Rheumatoid Arthritis by Degradable LPCE Nano-Conjugate-Delivered p65 siRNA.

Authors:  Xiaohua Chen; Bailing Zhou; Yan Gao; Kaiyu Wang; Jieping Wu; Ming Shuai; Ke Men; Xingmei Duan
Journal:  Pharmaceutics       Date:  2022-01-11       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.